Skip to main content
Erschienen in: Critical Care 1/2006

01.02.2005 | Commentary

Erythromycin for prokinesis: imprudent prescribing?

verfasst von: Martino Dall'Antonia, Mark Wilks, Pietro G Coen, Susan Bragman, Michael R Millar

Erschienen in: Critical Care | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

Problems with antibiotic resistant bacteria are increasing in the hospital and particularly in the intensive care unit. Methicillin-resistant Staphylococcus aureus, Acinetobacter baumanii and extended spectrum beta-lactamase producing Gram-negative bacilli constitute a therapeutic and infection control challenge. Early enteral feeding improves survival in patients in the intensive care unit. Prokinetic agents are routinely used in patients with inappropriate gastrointestinal motility. The use of erythromycin at sub-therapeutic doses as a prokinetic agent is a cause of concern for the following reasons: it can increase the emergence and spread of antibiotic resistance and the likelihood of Clostridium difficile disease. The use of an antibiotic as a prokinetic agent does not constitute prudent antimicrobial prescribing and should be avoided. Alternative agents, whenever possible, should be used.
Literatur
1.
Zurück zum Zitat Livermore DM: Minimising antibiotic resistance. Lancet Infect Dis 2005, 5: 450-459. 10.1016/S1473-3099(05)70166-3CrossRefPubMed Livermore DM: Minimising antibiotic resistance. Lancet Infect Dis 2005, 5: 450-459. 10.1016/S1473-3099(05)70166-3CrossRefPubMed
4.
Zurück zum Zitat Dall'Antonia M, Coen PG, Wilks M, Whiley A, Millar M: Competition between methicillin-sensitive and-resistant Staphylococcus aureus in the anterior nares. J Hosp Infect 2005, 61: 62-67. 10.1016/j.jhin.2005.01.008CrossRefPubMed Dall'Antonia M, Coen PG, Wilks M, Whiley A, Millar M: Competition between methicillin-sensitive and-resistant Staphylococcus aureus in the anterior nares. J Hosp Infect 2005, 61: 62-67. 10.1016/j.jhin.2005.01.008CrossRefPubMed
5.
Zurück zum Zitat Berg HF, Tjhie JH, Scheffer GJ, Peeters MF, van Keulen PH, Kluyt-mans JA, Stobberingh EE: Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of S. aureus after therapy with slow-release clarithromicin: a randomized, double-blind, placebo-controlled study. Antimicrob Agents Chemother 2004, 48: 4138-4188. 10.1128/AAC.48.11.4183-4188.2004CrossRef Berg HF, Tjhie JH, Scheffer GJ, Peeters MF, van Keulen PH, Kluyt-mans JA, Stobberingh EE: Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of S. aureus after therapy with slow-release clarithromicin: a randomized, double-blind, placebo-controlled study. Antimicrob Agents Chemother 2004, 48: 4138-4188. 10.1128/AAC.48.11.4183-4188.2004CrossRef
6.
Zurück zum Zitat Carsenti-Dellamonica H, Galimand M, Vandenbos F, Pradier C, Roger PM, Dunais B, Sabah M, Mancini G, Dellamonica P: In vitro selection of mutants of Streptococcus pneumoniae resistant to macrolides and linezolid: relationship with susceptibility to penicillin G or macrolides. J Antimicrob Chemother 2005, 56: 633-642. 10.1093/jac/dki301CrossRefPubMed Carsenti-Dellamonica H, Galimand M, Vandenbos F, Pradier C, Roger PM, Dunais B, Sabah M, Mancini G, Dellamonica P: In vitro selection of mutants of Streptococcus pneumoniae resistant to macrolides and linezolid: relationship with susceptibility to penicillin G or macrolides. J Antimicrob Chemother 2005, 56: 633-642. 10.1093/jac/dki301CrossRefPubMed
7.
Zurück zum Zitat Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC: Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366: 1079-1084. 10.1016/S0140-6736(05)67420-XCrossRefPubMed Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC: Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366: 1079-1084. 10.1016/S0140-6736(05)67420-XCrossRefPubMed
8.
Zurück zum Zitat John R, Brazier JS: Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. J Hosp Infect 2005, 61: 11-14. 10.1016/j.jhin.2005.01.020CrossRefPubMed John R, Brazier JS: Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. J Hosp Infect 2005, 61: 11-14. 10.1016/j.jhin.2005.01.020CrossRefPubMed
9.
Zurück zum Zitat Mullany P, Wilks M, Tabaqchali S: Transfer of macrolide-lin-cosamide-streptogramin B (MLS) resistance in Clostridium difficile is linked to a gene homologous with toxin A and is mediated by a conjugative transposon, Tn5398. J Antimicrob Chemother 1995, 35: 305-315.CrossRefPubMed Mullany P, Wilks M, Tabaqchali S: Transfer of macrolide-lin-cosamide-streptogramin B (MLS) resistance in Clostridium difficile is linked to a gene homologous with toxin A and is mediated by a conjugative transposon, Tn5398. J Antimicrob Chemother 1995, 35: 305-315.CrossRefPubMed
11.
Zurück zum Zitat Canadian Critical Care Society: Clinical Practice Guidelines for Nutritional Support in Mechanically Ventilated, Adult Critically Ill Patients. Toronto. 2003. Canadian Critical Care Society: Clinical Practice Guidelines for Nutritional Support in Mechanically Ventilated, Adult Critically Ill Patients. Toronto. 2003.
12.
Zurück zum Zitat Booth CM, Heyland DK, Paterson WG: Gastrointestinal promotility drugs in the critical care setting: a systematic review of the evidence. Crit Care Med 2002, 30: 1653-1654.CrossRef Booth CM, Heyland DK, Paterson WG: Gastrointestinal promotility drugs in the critical care setting: a systematic review of the evidence. Crit Care Med 2002, 30: 1653-1654.CrossRef
13.
Zurück zum Zitat Talle NJ, Tack J, Peeters T: What comes after macrolides and other motility stimulants? Gut 2001, 49: 317-318. Talle NJ, Tack J, Peeters T: What comes after macrolides and other motility stimulants? Gut 2001, 49: 317-318.
14.
Zurück zum Zitat Department of Health: Winning Ways: Report from the Chief Medical Officer. London. 2003. Department of Health: Winning Ways: Report from the Chief Medical Officer. London. 2003.
Metadaten
Titel
Erythromycin for prokinesis: imprudent prescribing?
verfasst von
Martino Dall'Antonia
Mark Wilks
Pietro G Coen
Susan Bragman
Michael R Millar
Publikationsdatum
01.02.2005
Verlag
BioMed Central
Erschienen in
Critical Care / Ausgabe 1/2006
Elektronische ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc3956

Weitere Artikel der Ausgabe 1/2006

Critical Care 1/2006 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.